Pegteograstim may be effective for reducing chemotherapy-induced neutropenia
the ONA take:
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer undergoing myelosuppressive chemotherapy, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the phase 2/3 study, researchers sought to evaluate the efficacy and safety of pegteograstim, a new formulation of pegylated granulocyte-colony-stimulating factor (G-CSF), compared with pegfilgrastim in preventing febrile neutropenia.
In the phase 3 portion, researchers enrolled 117 patients with breast cancer who were undergoing treatment with docetaxel plus doxorubicin or docetaxel plus doxorubicin and cyclophosphamide.
Patients were randomly assigned to receive pegteofilgrastim 6.0 mg subcutaneously on day 2 of chemotherapy or pegfilgrastim 6.0 mg subcutaneously.
Results showed that the efficacy of pegteograstim was noninferior to that of pegfilgrastim in the duration of grade 4 neutropenia during cycle 1 of chemotherapy.
Furthermore, the time to absolute neutrophil count recovery was significantly shorter with pegteograstim compared with pegfilgrastim.
In regard to safety, treatment-related adverse events did not differ significantly between the two treatment arms.
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|